BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8765530)

  • 1. Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505.
    Cummings J; Meikle I; Macpherson JS; Smyth JF
    Anticancer Drug Des; 1996 Jul; 11(5):367-82. PubMed ID: 8765530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance.
    Cummings J; Macpherson JS; Meikle I; Smyth JF
    Biochem Pharmacol; 1996 Oct; 52(7):979-90. PubMed ID: 8831716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs.
    Meikle I; Cummings J; Macpherson JS; Smyth JF
    Anticancer Drug Des; 1995 Oct; 10(7):515-27. PubMed ID: 7495476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography.
    Cummings J; Meikle I; Macpherson JS; Smyth JF
    J Chromatogr B Biomed Appl; 1996 Oct; 685(1):159-64. PubMed ID: 8930764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
    Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC
    Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates.
    Meikle I; Cummings J; Macpherson JS; Hadfield JA; Smyth JF
    Biochem Pharmacol; 1995 Jun; 49(12):1747-57. PubMed ID: 7598737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
    Parajuli P; Yano S; Nishioka Y; Nokihara H; Hanibuchi M; Nishimura N; Utsugi T; Sone S
    Oncol Res; 1999; 11(5):219-24. PubMed ID: 10608616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
    Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
    Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
    Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
    J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
    Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
    Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
    Cummings J; Boyd G; Ethell BT; Macpherson JS; Burchell B; Smyth JF; Jodrell DI
    Biochem Pharmacol; 2002 Feb; 63(4):607-13. PubMed ID: 11992628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.
    Meikle I; Cummings J; Macpherson JS; Smyth JF
    Br J Cancer; 1996 Aug; 74(3):374-9. PubMed ID: 8695351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model.
    Ciomei M; Croci V; Ciavolella A; Ballinari D; Pesenti E
    Clin Cancer Res; 2006 May; 12(9):2856-61. PubMed ID: 16675581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
    Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
    Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU/ICRF 500.
    Cummings J; Sumner AT; Slavotinek A; Meikle I; Macpherson JS; Smyth JF
    Mutat Res; 1995 Aug; 344(1-2):55-62. PubMed ID: 7565893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.